Following the record surge in COVID-19 cases during the Omicron-driven wave, some 58 percent of the U.S. population overall and more than 75 percent of younger children have been infected with the coronavirus since the start of the pandemic, according to a U.S. nationwide blood survey released on April 26.
Gilead’s Veklury Becomes First FDA-Approved COVID-19 Treatment for Young Children
Antivirals, Children, COVID-19 Therapeutics, FDA, Gilead, Hospitalized COVID-19 Patients, National Institute of Allergy and Infectious Diseases (NIAID), Pharmacokinetic Data, R&D, Remdesivir, Safety Data, Therapeutics, World Health Organization, Young childrenThe U.S. Food and Drug Administration approved Gilead Sciences’ antiviral therapy Veklury (remdesivir) as the first treatment for COVID-19 in young children.